Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WAYNE HARPER

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1376538926
CMS profile
197757
Location
RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$14.65

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $14.65 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $14.65 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WAYNE HARPER

NPI 1376538926 · CMS profile ID 197757

Allopathic & Osteopathic Physicians / Internal Medicine

RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1376538926?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WAYNE HARPER, NPI 1376538926, CMS profile ID 197757. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376538926?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). WAYNE HARPER, NPI 1376538926, CMS profile ID 197757. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376538926?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
WAYNE HARPER, NPI 1376538926, CMS profile ID 197757, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1376538926?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $14.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $14.6504/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997438869 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $20.00 1
PY2023 $14.65 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2022 Principal investigator $74,594.70 18
PY2021 Principal investigator $2,376,430.02 49
PY2020 Principal investigator $3,589,740.22 82
PY2019 Recipient $9,290.45 2
PY2019 Principal investigator $696,096.81 90

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

82 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,270.72 12/31/2020 Non-covered Recipient Entity
M3 Wake Research, Inc
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740107837
Principal investigator 1 SANOFI PASTEUR INC. $686.47 12/29/2020 Non-covered Recipient Entity
M3 Wake Research,Inc
HSV15 Safety and Efficacy of 4 Investigational HSV 2 Vaccines Administered by Intramuscular Route in Adults with Recurrent Genital Herpes Caused by HSV 2 No dispute reported 06/30/2026 744044065
Principal investigator 1 Janssen Research & Development, LLC $792,398.00 12/22/2020 Non-covered Recipient Entity
M3 Wake Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants No dispute reported 06/30/2026 719504943
Principal investigator 1 PFIZER INC. $20,280.00 12/16/2020 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742894493
Principal investigator 1 SANOFI PASTEUR INC. $30,050.00 12/08/2020 Non-covered Recipient Entity
M3 Wake Research,Inc
HSV15 Safety and Efficacy of 4 Investigational HSV 2 Vaccines Administered by Intramuscular Route in Adults with Recurrent Genital Herpes Caused by HSV 2 No dispute reported 06/30/2026 744044051
Principal investigator 1 Seqirus USA Inc $15,196.50 12/08/2020 Non-covered Recipient Entity
M3 Wake Research, Inc
Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 746691777
Principal investigator 1 Janssen Research & Development, LLC $8,000.00 12/03/2020 Non-covered Recipient Entity
M3 Wake Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants No dispute reported 06/30/2026 719504939
Principal investigator 1 PFIZER INC. $2,535.00 12/03/2020 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742893105
Principal investigator 1 SANOFI PASTEUR INC. $39,288.33 12/03/2020 Non-covered Recipient Entity
M3 Wake Research,Inc
HSV15 Safety and Efficacy of 4 Investigational HSV 2 Vaccines Administered by Intramuscular Route in Adults with Recurrent Genital Herpes Caused by HSV 2 No dispute reported 06/30/2026 744044029
Principal investigator 1 PFIZER INC. $149,745.95 11/28/2020 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742913765
Principal investigator 1 Janssen Research & Development, LLC $482,633.00 11/24/2020 Non-covered Recipient Entity
M3 Wake Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants No dispute reported 06/30/2026 719504935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $950.00 11/24/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724479609
Principal investigator 1 PFIZER INC. $33,429.50 11/21/2020 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742854976
Principal investigator 1 PFIZER INC. $76,344.46 11/21/2020 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742913701
Principal investigator 1 PFIZER INC. $6,825.00 11/21/2020 Non-covered Recipient Entity
WRMount Vernon Clinical Research LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF06865571 DGAT2I ALONE AND WHEN COADMINISTERED WITH PF05221304 ACCI IN ADULT PARTICIPANTS WITH BIOPSYCONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3 No dispute reported 06/30/2026 742917953
Principal investigator 1 PFIZER INC. $10,569.14 11/18/2020 Non-covered Recipient Entity
CAROLINA PHASE RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742917949
Principal investigator 1 PFIZER INC. $87,036.64 11/17/2020 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742913769
Principal investigator 1 Seqirus USA Inc $49,523.40 11/17/2020 Non-covered Recipient Entity
M3 Wake Research, Inc
Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 746691771
Principal investigator 1 Seqirus USA Inc $1,408.00 11/12/2020 Non-covered Recipient Entity
M3 Wake Research, Inc
Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 746691767
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,614.00 11/11/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 740107833
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 11/11/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 740107835
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 11/10/2020 Non-covered Recipient Entity
M3 Wake Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants No dispute reported 06/30/2026 719504931
Principal investigator 1 PFIZER INC. $167,727.50 11/07/2020 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742913699
Principal investigator 1 SANOFI PASTEUR INC. $29,660.40 11/03/2020 Non-covered Recipient Entity
M3 Wake Research,Inc
HSV15 Safety and Efficacy of 4 Investigational HSV 2 Vaccines Administered by Intramuscular Route in Adults with Recurrent Genital Herpes Caused by HSV 2 No dispute reported 06/30/2026 744044017
Principal investigator 1 Bavarian Nordic A/S $70,783.00 11/01/2020 Non-covered Recipient Entity
M3 Wake Research Associates
POX-MVA-031: Freeze-Dried MVA-BN Lot Consistency Smallpox Trial No dispute reported 06/30/2026 735529881
Principal investigator 1 PFIZER INC. $174,029.90 10/31/2020 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742913635
Principal investigator 1 Novo Nordisk AS $15,354.17 10/29/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
NN9536-4376 No dispute reported 06/30/2026 742337565
Principal investigator 1 Janssen Research & Development, LLC $94,328.00 10/26/2020 Non-covered Recipient Entity
M3 Wake Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants No dispute reported 06/30/2026 719504927
Principal investigator 1 PFIZER INC. $151,276.64 10/23/2020 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742913975
Principal investigator 1 PFIZER INC. $184,844.51 10/20/2020 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742913630
Principal investigator 1 PFIZER INC. $260,181.80 10/10/2020 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742913695
Principal investigator 1 PFIZER INC. $7,089.00 10/02/2020 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742854973
Principal investigator 1 PFIZER INC. $152,227.82 10/02/2020 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742913633
Principal investigator 1 SANOFI PASTEUR INC. $33,361.90 09/17/2020 Non-covered Recipient Entity
M3 Wake Research,Inc
HSV15 Safety and Efficacy of 4 Investigational HSV 2 Vaccines Administered by Intramuscular Route in Adults with Recurrent Genital Herpes Caused by HSV 2 No dispute reported 06/30/2026 744044007
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,466.78 09/16/2020 Non-covered Recipient Entity
M3 Wake Research, Inc.
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740107853
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 09/15/2020 Non-covered Recipient Entity
M3 Wake Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants No dispute reported 06/30/2026 719504919
Principal investigator 1 Janssen Research & Development, LLC $12,000.00 09/15/2020 Non-covered Recipient Entity
M3 Wake Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants No dispute reported 06/30/2026 719504923
Principal investigator 1 SANOFI PASTEUR INC. $1,200.00 09/15/2020 Non-covered Recipient Entity
M3 Wake Research,Inc
MEQ00066 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal MenACYW Conjugate Vaccine in Older Adults Who Received a Primary Vaccination 3 or More Years Earlier in Study MET49 No dispute reported 06/30/2026 744043995
Principal investigator 1 Bavarian Nordic A/S $3,662.00 09/01/2020 Non-covered Recipient Entity
M3 Wake Research Associates
POX-MVA-031: Freeze-Dried MVA-BN Lot Consistency Smallpox Trial No dispute reported 06/30/2026 735529863
Principal investigator 1 Bavarian Nordic A/S $94,050.00 09/01/2020 Non-covered Recipient Entity
M3 Wake Research Associates
POX-MVA-031: Freeze-Dried MVA-BN Lot Consistency Smallpox Trial No dispute reported 06/30/2026 735529865
Principal investigator 1 PFIZER INC. $1,057.66 08/31/2020 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742855875
Principal investigator 1 Novo Nordisk AS $7,154.37 08/27/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
NN9536-4376 No dispute reported 06/30/2026 742337563
Principal investigator 1 PFIZER INC. $3,434.54 08/19/2020 Non-covered Recipient Entity
CAROLINA PHASE RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742917903
Principal investigator 1 Bavarian Nordic A/S $956.00 08/01/2020 Non-covered Recipient Entity
M3 Wake Research Associates
POX-MVA-031: Freeze-Dried MVA-BN Lot Consistency Smallpox Trial No dispute reported 06/30/2026 735529867
Principal investigator 1 SANOFI PASTEUR INC. $78.74 07/28/2020 Non-covered Recipient Entity
M3 Wake Research,Inc
HSV15 Safety and Efficacy of 4 Investigational HSV 2 Vaccines Administered by Intramuscular Route in Adults with Recurrent Genital Herpes Caused by HSV 2 No dispute reported 06/30/2026 744043973
Principal investigator 1 PFIZER INC. $298.28 07/22/2020 Non-covered Recipient Entity
Carolina Phase 1 Research LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742917899
Principal investigator 1 SANOFI PASTEUR INC. $23,293.80 07/21/2020 Non-covered Recipient Entity
M3 Wake Research,Inc
HSV15 Safety and Efficacy of 4 Investigational HSV 2 Vaccines Administered by Intramuscular Route in Adults with Recurrent Genital Herpes Caused by HSV 2 No dispute reported 06/30/2026 744043959
Principal investigator 1 Becton, Dickinson and Company $33,050.00 07/20/2020 Non-covered Recipient Entity
M3 Wake Research, Inc
Veritor Antigen Assay No dispute reported 06/30/2026 748084459
Principal investigator 1 PFIZER INC. $6,575.00 07/17/2020 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 2B RANDOMIZED OBSERVERBLINDED TRIAL TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY ADMINISTERED ON 2 DIFFERENT DOSING SCHEDULES IN HEALTHY PARTICIPANTS 11 TO 15 YEARS OF AGE No dispute reported 06/30/2026 742941255
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.66 07/16/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724470566
Principal investigator 1 PFIZER INC. $21,539.91 07/02/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 742940449
Principal investigator 1 PFIZER INC. $1,528.32 07/02/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742940453
Principal investigator 1 PFIZER INC. $80.43 07/02/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742941519
Principal investigator 1 PFIZER INC. $6,825.00 07/01/2020 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF06865571 DGAT2I ALONE AND WHEN COADMINISTERED WITH PF05221304 ACCI IN ADULT PARTICIPANTS WITH BIOPSYCONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3 No dispute reported 06/30/2026 742941251
Principal investigator 1 PFIZER INC. $882.33 06/04/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742940447
Principal investigator 1 PFIZER INC. $2,699.94 06/04/2020 Non-covered Recipient Entity
CAROLINA PHASE RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742956575
Principal investigator 1 PFIZER INC. $1,100.00 05/27/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
A PHASE 3 MULTICENTER LONGTERM OBSERVATIONAL STUDY OF SUBJECTS FROM TANEZUMAB STUDIES WHO UNDERGO A TOTAL KNEE HIP OR SHOULDER REPLACEMENT No dispute reported 06/30/2026 742956549
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,320.50 05/21/2020 Non-covered Recipient Entity
M3 Wake Research, Inc.
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740107849
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $33.22 05/21/2020 Non-covered Recipient Entity
M3 Wake Research, Inc.
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740107851
Principal investigator 1 PFIZER INC. $8,223.87 05/08/2020 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742935211
Principal investigator 1 PFIZER INC. $18,389.33 04/30/2020 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 742934901
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,282.00 04/27/2020 Non-covered Recipient Entity
M3 Wake Research, Inc.
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740107847
Principal investigator 1 Novo Nordisk AS $68,315.13 04/16/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
NN9536-4376 No dispute reported 06/30/2026 742337561
Principal investigator 1 PFIZER INC. $7,459.41 04/14/2020 Non-covered Recipient Entity
CAROLINA PHASE RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742956547
Principal investigator 1 PFIZER INC. $263.74 04/07/2020 Non-covered Recipient Entity
CAROLINA PHASE RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742956573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $97.70 03/26/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724458717
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,320.50 03/19/2020 Non-covered Recipient Entity
M3 Wake Research, Inc.
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740107843
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $33.22 03/19/2020 Non-covered Recipient Entity
M3 Wake Research, Inc.
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740107845
Principal investigator 1 SANOFI PASTEUR INC. $1,334.50 03/17/2020 Non-covered Recipient Entity
Wake Research Association
HSV15 Safety and Efficacy of 4 Investigational HSV 2 Vaccines Administered by Intramuscular Route in Adults with Recurrent Genital Herpes Caused by HSV 2 No dispute reported 06/30/2026 744041277
Principal investigator 1 SANOFI PASTEUR INC. $6,000.00 02/25/2020 Non-covered Recipient Entity
M3 Wake Research,Inc
MEQ00066 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal MenACYW Conjugate Vaccine in Older Adults Who Received a Primary Vaccination 3 or More Years Earlier in Study MET49 No dispute reported 06/30/2026 744043885
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,994.50 02/24/2020 Non-covered Recipient Entity
M3 Wake Research, Inc.
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740107841
Principal investigator 1 PFIZER INC. $42,027.07 02/20/2020 Non-covered Recipient Entity
CAROLINA PHASE RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742971773
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 02/17/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860 No dispute reported 06/30/2026 719530729
Principal investigator 1 PFIZER INC. $841.02 01/31/2020 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742937043
Principal investigator 1 PFIZER INC. $1,807.25 01/28/2020 Non-covered Recipient Entity
CAROLINA PHASE RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742971771
Principal investigator 1 PFIZER INC. $727.00 01/28/2020 Non-covered Recipient Entity
CAROLINA PHASE RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742973337
Principal investigator 1 SANOFI PASTEUR INC. $5,800.00 01/28/2020 Non-covered Recipient Entity
M3 Wake Research,Inc
MEQ00066 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal MenACYW Conjugate Vaccine in Older Adults Who Received a Primary Vaccination 3 or More Years Earlier in Study MET49 No dispute reported 06/30/2026 744043848
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $712.50 01/28/2020 Non-covered Recipient Entity
M3 Wake Research, Inc.
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740107839
Principal investigator 1 SANOFI PASTEUR INC. $9,650.00 01/23/2020 Non-covered Recipient Entity
M3 Wake Research,Inc
MEQ00066 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal MenACYW Conjugate Vaccine in Older Adults Who Received a Primary Vaccination 3 or More Years Earlier in Study MET49 No dispute reported 06/30/2026 744043835
Principal investigator 1 PFIZER INC. $1,402.25 01/15/2020 Non-covered Recipient Entity
CAROLINA PHASE RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742971765
Principal investigator 1 PFIZER INC. $1,105.00 01/15/2020 Non-covered Recipient Entity
CAROLINA PHASE RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742973346
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $18,000.00 01/04/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
A PHASE 4, OPEN-LABEL, SINGLE DOSE STUDY TO EVALUATE SUNOSITM (SOLRIAMFETOL) PHARMACOKINETICS IN BREAST MILK OF HEALTHY POSTPARTUM WOMEN FOLLOWING ORAL ADMINISTRATION OF SUNOSITM No dispute reported 06/30/2026 744483041